Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase 1/2 trial in adults.
Identifieur interne : 000623 ( Main/Exploration ); précédent : 000622; suivant : 000624Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase 1/2 trial in adults.
Auteurs : Joanne M. Langley [Canada] ; Louise Frenette ; Linda Ferguson ; Dennis Riff ; Eric Sheldon ; George Risi ; Casey Johnson ; Ping Li ; Richard Kenney ; Bruce Innis ; Louis FriesSource :
- The Journal of infectious diseases [ 1537-6613 ] ; 2010.
Descripteurs français
- KwdFr :
- Adjuvants immunologiques (administration et posologie), Adolescent (MeSH), Adulte (MeSH), Adulte d'âge moyen (MeSH), Anticorps antiviraux (sang), Anticorps neutralisants (sang), Canada (MeSH), Femelle (MeSH), Grippe humaine (immunologie), Grippe humaine (prévention et contrôle), Humains (MeSH), Jeune adulte (MeSH), Mâle (MeSH), Rappel de vaccin (méthodes), Réactions croisées (MeSH), Sous-type H5N1 du virus de la grippe A (immunologie), Vaccination (méthodes), Vaccins antigrippaux (administration et posologie), Vaccins antigrippaux (effets indésirables), Vaccins antigrippaux (immunologie), États-Unis (MeSH).
- MESH :
- administration et posologie : Adjuvants immunologiques, Vaccins antigrippaux.
- effets indésirables : Vaccins antigrippaux.
- immunologie : Grippe humaine, Sous-type H5N1 du virus de la grippe A, Vaccins antigrippaux.
- méthodes : Rappel de vaccin, Vaccination.
- prévention et contrôle : Grippe humaine.
- sang : Anticorps antiviraux, Anticorps neutralisants.
- Adolescent, Adulte, Adulte d'âge moyen, Canada, Femelle, Humains, Jeune adulte, Mâle, Réactions croisées, États-Unis.
- Wicri :
- geographic : Canada, États-Unis.
English descriptors
- KwdEn :
- Adjuvants, Immunologic (administration & dosage), Adolescent (MeSH), Adult (MeSH), Antibodies, Neutralizing (blood), Antibodies, Viral (blood), Canada (MeSH), Cross Reactions (MeSH), Female (MeSH), Humans (MeSH), Immunization, Secondary (methods), Influenza A Virus, H5N1 Subtype (immunology), Influenza Vaccines (administration & dosage), Influenza Vaccines (adverse effects), Influenza Vaccines (immunology), Influenza, Human (immunology), Influenza, Human (prevention & control), Male (MeSH), Middle Aged (MeSH), United States (MeSH), Vaccination (methods), Young Adult (MeSH).
- MESH :
- chemical , administration & dosage : Adjuvants, Immunologic, Influenza Vaccines.
- chemical , adverse effects : Influenza Vaccines.
- chemical , blood : Antibodies, Neutralizing, Antibodies, Viral.
- chemical , immunology : Influenza Vaccines.
- geographic : Canada, United States.
- immunology : Influenza A Virus, H5N1 Subtype, Influenza, Human.
- methods : Immunization, Secondary, Vaccination.
- prevention & control : Influenza, Human.
- Adolescent, Adult, Cross Reactions, Female, Humans, Male, Middle Aged, Young Adult.
Abstract
BACKGROUND
The tocopherol-based oil-in-water emulsion adjuvant system family (AS03) improves antigen sparing with split-virion H5N1 influenza vaccines, representing an important development for pandemic preparedness. In this phase 1/2 randomized, controlled, observer-blinded study in 680 adults, we assessed the immunogenicity and safety of A/Indonesia/5/05 H5N1 (IBCDC-RG2, clade 2.1) prepandemic candidate vaccines produced at 2 separate manufacturing sites.
METHODS
Two doses, each of which contained 3.75 microg of hemagglutinin antigen, were given 21 days apart either without adjuvant or with an adjuvant system containing 11.86 mg or 5.93 mg of tocopherol (AS03).
RESULTS
The AS03-adjuvanted A/Indonesia/05/2005 (NIBRG-14) vaccines were significantly more immunogenic than nonadjuvanted vaccine in homologous assays. Neutralizing cross-clade immunogenicity against clades 1, 2.2, and 2.3 was demonstrated at day 42 with all vaccines; at 6 months, seroconversion rates were highest for clade 2.2 (60.7%) and for clade 1 (38.3%). Adjuvantation was associated with increased short-term injection-site reactions (pain) in 80% of participants, with such reactions assessed as being of grade 3 severity for 4.0% of doses. No other safety or reactogenicity concerns were identified over 6 months of follow-up.
CONCLUSIONS
Humoral responses against the adjuvanted 3.75-microg hemagglutinin antigen vaccines from both manufacturing sites fulfilled European and US licensure criteria for immunogenicity for influenza vaccines.
DOI: 10.1086/652701
PubMed: 20423222
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase 1/2 trial in adults.</title><author><name sortKey="Langley, Joanne M" sort="Langley, Joanne M" uniqKey="Langley J" first="Joanne M" last="Langley">Joanne M. Langley</name><affiliation wicri:level="1"><nlm:affiliation>Canadian Center for Vaccinology, Dalhousie University and IWK Health Centre Halifax, Halifax, Nova Scotia, Canada. jmlangle@dal.ca</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Canadian Center for Vaccinology, Dalhousie University and IWK Health Centre Halifax, Halifax, Nova Scotia</wicri:regionArea><wicri:noRegion>Nova Scotia</wicri:noRegion></affiliation></author><author><name sortKey="Frenette, Louise" sort="Frenette, Louise" uniqKey="Frenette L" first="Louise" last="Frenette">Louise Frenette</name></author><author><name sortKey="Ferguson, Linda" sort="Ferguson, Linda" uniqKey="Ferguson L" first="Linda" last="Ferguson">Linda Ferguson</name></author><author><name sortKey="Riff, Dennis" sort="Riff, Dennis" uniqKey="Riff D" first="Dennis" last="Riff">Dennis Riff</name></author><author><name sortKey="Sheldon, Eric" sort="Sheldon, Eric" uniqKey="Sheldon E" first="Eric" last="Sheldon">Eric Sheldon</name></author><author><name sortKey="Risi, George" sort="Risi, George" uniqKey="Risi G" first="George" last="Risi">George Risi</name></author><author><name sortKey="Johnson, Casey" sort="Johnson, Casey" uniqKey="Johnson C" first="Casey" last="Johnson">Casey Johnson</name></author><author><name sortKey="Li, Ping" sort="Li, Ping" uniqKey="Li P" first="Ping" last="Li">Ping Li</name></author><author><name sortKey="Kenney, Richard" sort="Kenney, Richard" uniqKey="Kenney R" first="Richard" last="Kenney">Richard Kenney</name></author><author><name sortKey="Innis, Bruce" sort="Innis, Bruce" uniqKey="Innis B" first="Bruce" last="Innis">Bruce Innis</name></author><author><name sortKey="Fries, Louis" sort="Fries, Louis" uniqKey="Fries L" first="Louis" last="Fries">Louis Fries</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2010">2010</date><idno type="RBID">pubmed:20423222</idno><idno type="pmid">20423222</idno><idno type="doi">10.1086/652701</idno><idno type="wicri:Area/Main/Corpus">000658</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000658</idno><idno type="wicri:Area/Main/Curation">000658</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000658</idno><idno type="wicri:Area/Main/Exploration">000658</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase 1/2 trial in adults.</title><author><name sortKey="Langley, Joanne M" sort="Langley, Joanne M" uniqKey="Langley J" first="Joanne M" last="Langley">Joanne M. Langley</name><affiliation wicri:level="1"><nlm:affiliation>Canadian Center for Vaccinology, Dalhousie University and IWK Health Centre Halifax, Halifax, Nova Scotia, Canada. jmlangle@dal.ca</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Canadian Center for Vaccinology, Dalhousie University and IWK Health Centre Halifax, Halifax, Nova Scotia</wicri:regionArea><wicri:noRegion>Nova Scotia</wicri:noRegion></affiliation></author><author><name sortKey="Frenette, Louise" sort="Frenette, Louise" uniqKey="Frenette L" first="Louise" last="Frenette">Louise Frenette</name></author><author><name sortKey="Ferguson, Linda" sort="Ferguson, Linda" uniqKey="Ferguson L" first="Linda" last="Ferguson">Linda Ferguson</name></author><author><name sortKey="Riff, Dennis" sort="Riff, Dennis" uniqKey="Riff D" first="Dennis" last="Riff">Dennis Riff</name></author><author><name sortKey="Sheldon, Eric" sort="Sheldon, Eric" uniqKey="Sheldon E" first="Eric" last="Sheldon">Eric Sheldon</name></author><author><name sortKey="Risi, George" sort="Risi, George" uniqKey="Risi G" first="George" last="Risi">George Risi</name></author><author><name sortKey="Johnson, Casey" sort="Johnson, Casey" uniqKey="Johnson C" first="Casey" last="Johnson">Casey Johnson</name></author><author><name sortKey="Li, Ping" sort="Li, Ping" uniqKey="Li P" first="Ping" last="Li">Ping Li</name></author><author><name sortKey="Kenney, Richard" sort="Kenney, Richard" uniqKey="Kenney R" first="Richard" last="Kenney">Richard Kenney</name></author><author><name sortKey="Innis, Bruce" sort="Innis, Bruce" uniqKey="Innis B" first="Bruce" last="Innis">Bruce Innis</name></author><author><name sortKey="Fries, Louis" sort="Fries, Louis" uniqKey="Fries L" first="Louis" last="Fries">Louis Fries</name></author></analytic><series><title level="j">The Journal of infectious diseases</title><idno type="eISSN">1537-6613</idno><imprint><date when="2010" type="published">2010</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adjuvants, Immunologic (administration & dosage)</term><term>Adolescent (MeSH)</term><term>Adult (MeSH)</term><term>Antibodies, Neutralizing (blood)</term><term>Antibodies, Viral (blood)</term><term>Canada (MeSH)</term><term>Cross Reactions (MeSH)</term><term>Female (MeSH)</term><term>Humans (MeSH)</term><term>Immunization, Secondary (methods)</term><term>Influenza A Virus, H5N1 Subtype (immunology)</term><term>Influenza Vaccines (administration & dosage)</term><term>Influenza Vaccines (adverse effects)</term><term>Influenza Vaccines (immunology)</term><term>Influenza, Human (immunology)</term><term>Influenza, Human (prevention & control)</term><term>Male (MeSH)</term><term>Middle Aged (MeSH)</term><term>United States (MeSH)</term><term>Vaccination (methods)</term><term>Young Adult (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adjuvants immunologiques (administration et posologie)</term><term>Adolescent (MeSH)</term><term>Adulte (MeSH)</term><term>Adulte d'âge moyen (MeSH)</term><term>Anticorps antiviraux (sang)</term><term>Anticorps neutralisants (sang)</term><term>Canada (MeSH)</term><term>Femelle (MeSH)</term><term>Grippe humaine (immunologie)</term><term>Grippe humaine (prévention et contrôle)</term><term>Humains (MeSH)</term><term>Jeune adulte (MeSH)</term><term>Mâle (MeSH)</term><term>Rappel de vaccin (méthodes)</term><term>Réactions croisées (MeSH)</term><term>Sous-type H5N1 du virus de la grippe A (immunologie)</term><term>Vaccination (méthodes)</term><term>Vaccins antigrippaux (administration et posologie)</term><term>Vaccins antigrippaux (effets indésirables)</term><term>Vaccins antigrippaux (immunologie)</term><term>États-Unis (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Adjuvants, Immunologic</term><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en"><term>Antibodies, Neutralizing</term><term>Antibodies, Viral</term></keywords><keywords scheme="MESH" type="chemical" qualifier="immunology" xml:lang="en"><term>Influenza Vaccines</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>Canada</term><term>United States</term></keywords><keywords scheme="MESH" qualifier="administration et posologie" xml:lang="fr"><term>Adjuvants immunologiques</term><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" qualifier="effets indésirables" xml:lang="fr"><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" qualifier="immunologie" xml:lang="fr"><term>Grippe humaine</term><term>Sous-type H5N1 du virus de la grippe A</term><term>Vaccins antigrippaux</term></keywords><keywords scheme="MESH" qualifier="immunology" xml:lang="en"><term>Influenza A Virus, H5N1 Subtype</term><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Immunization, Secondary</term><term>Vaccination</term></keywords><keywords scheme="MESH" qualifier="méthodes" xml:lang="fr"><term>Rappel de vaccin</term><term>Vaccination</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Influenza, Human</term></keywords><keywords scheme="MESH" qualifier="prévention et contrôle" xml:lang="fr"><term>Grippe humaine</term></keywords><keywords scheme="MESH" qualifier="sang" xml:lang="fr"><term>Anticorps antiviraux</term><term>Anticorps neutralisants</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Cross Reactions</term><term>Female</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Young Adult</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Canada</term><term>Femelle</term><term>Humains</term><term>Jeune adulte</term><term>Mâle</term><term>Réactions croisées</term><term>États-Unis</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Canada</term><term>États-Unis</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p><b>BACKGROUND</b></p><p>The tocopherol-based oil-in-water emulsion adjuvant system family (AS03) improves antigen sparing with split-virion H5N1 influenza vaccines, representing an important development for pandemic preparedness. In this phase 1/2 randomized, controlled, observer-blinded study in 680 adults, we assessed the immunogenicity and safety of A/Indonesia/5/05 H5N1 (IBCDC-RG2, clade 2.1) prepandemic candidate vaccines produced at 2 separate manufacturing sites.</p></div><div type="abstract" xml:lang="en"><p><b>METHODS</b></p><p>Two doses, each of which contained 3.75 microg of hemagglutinin antigen, were given 21 days apart either without adjuvant or with an adjuvant system containing 11.86 mg or 5.93 mg of tocopherol (AS03).</p></div><div type="abstract" xml:lang="en"><p><b>RESULTS</b></p><p>The AS03-adjuvanted A/Indonesia/05/2005 (NIBRG-14) vaccines were significantly more immunogenic than nonadjuvanted vaccine in homologous assays. Neutralizing cross-clade immunogenicity against clades 1, 2.2, and 2.3 was demonstrated at day 42 with all vaccines; at 6 months, seroconversion rates were highest for clade 2.2 (60.7%) and for clade 1 (38.3%). Adjuvantation was associated with increased short-term injection-site reactions (pain) in 80% of participants, with such reactions assessed as being of grade 3 severity for 4.0% of doses. No other safety or reactogenicity concerns were identified over 6 months of follow-up.</p></div><div type="abstract" xml:lang="en"><p><b>CONCLUSIONS</b></p><p>Humoral responses against the adjuvanted 3.75-microg hemagglutinin antigen vaccines from both manufacturing sites fulfilled European and US licensure criteria for immunogenicity for influenza vaccines.</p></div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">20423222</PMID><DateCompleted><Year>2010</Year><Month>05</Month><Day>10</Day></DateCompleted><DateRevised><Year>2010</Year><Month>04</Month><Day>30</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1537-6613</ISSN><JournalIssue CitedMedium="Internet"><Volume>201</Volume><Issue>11</Issue><PubDate><Year>2010</Year><Month>Jun</Month><Day>01</Day></PubDate></JournalIssue><Title>The Journal of infectious diseases</Title><ISOAbbreviation>J. Infect. Dis.</ISOAbbreviation></Journal><ArticleTitle>Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase 1/2 trial in adults.</ArticleTitle><Pagination><MedlinePgn>1644-53</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1086/652701</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">The tocopherol-based oil-in-water emulsion adjuvant system family (AS03) improves antigen sparing with split-virion H5N1 influenza vaccines, representing an important development for pandemic preparedness. In this phase 1/2 randomized, controlled, observer-blinded study in 680 adults, we assessed the immunogenicity and safety of A/Indonesia/5/05 H5N1 (IBCDC-RG2, clade 2.1) prepandemic candidate vaccines produced at 2 separate manufacturing sites.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Two doses, each of which contained 3.75 microg of hemagglutinin antigen, were given 21 days apart either without adjuvant or with an adjuvant system containing 11.86 mg or 5.93 mg of tocopherol (AS03).</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The AS03-adjuvanted A/Indonesia/05/2005 (NIBRG-14) vaccines were significantly more immunogenic than nonadjuvanted vaccine in homologous assays. Neutralizing cross-clade immunogenicity against clades 1, 2.2, and 2.3 was demonstrated at day 42 with all vaccines; at 6 months, seroconversion rates were highest for clade 2.2 (60.7%) and for clade 1 (38.3%). Adjuvantation was associated with increased short-term injection-site reactions (pain) in 80% of participants, with such reactions assessed as being of grade 3 severity for 4.0% of doses. No other safety or reactogenicity concerns were identified over 6 months of follow-up.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Humoral responses against the adjuvanted 3.75-microg hemagglutinin antigen vaccines from both manufacturing sites fulfilled European and US licensure criteria for immunogenicity for influenza vaccines.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Langley</LastName><ForeName>Joanne M</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Canadian Center for Vaccinology, Dalhousie University and IWK Health Centre Halifax, Halifax, Nova Scotia, Canada. jmlangle@dal.ca</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Frenette</LastName><ForeName>Louise</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Ferguson</LastName><ForeName>Linda</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Riff</LastName><ForeName>Dennis</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Sheldon</LastName><ForeName>Eric</ForeName><Initials>E</Initials></Author><Author ValidYN="Y"><LastName>Risi</LastName><ForeName>George</ForeName><Initials>G</Initials></Author><Author ValidYN="Y"><LastName>Johnson</LastName><ForeName>Casey</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Ping</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Kenney</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Innis</LastName><ForeName>Bruce</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Fries</LastName><ForeName>Louis</ForeName><Initials>L</Initials></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT00510874</AccessionNumber></AccessionNumberList></DataBank></DataBankList><PublicationTypeList><PublicationType UI="D017426">Clinical Trial, Phase I</PublicationType><PublicationType UI="D017427">Clinical Trial, Phase II</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Infect Dis</MedlineTA><NlmUniqueID>0413675</NlmUniqueID><ISSNLinking>0022-1899</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000276">Adjuvants, Immunologic</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D057134">Antibodies, Neutralizing</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000914">Antibodies, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007252">Influenza Vaccines</NameOfSubstance></Chemical></ChemicalList><CitationSubset>AIM</CitationSubset><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000276" MajorTopicYN="N">Adjuvants, Immunologic</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="Y">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057134" MajorTopicYN="N">Antibodies, Neutralizing</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000914" MajorTopicYN="N">Antibodies, Viral</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002170" MajorTopicYN="N" Type="Geographic">Canada</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003429" MajorTopicYN="N">Cross Reactions</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007117" MajorTopicYN="N">Immunization, Secondary</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053124" MajorTopicYN="N">Influenza A Virus, H5N1 Subtype</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007252" MajorTopicYN="N">Influenza Vaccines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014611" MajorTopicYN="N">Vaccination</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2010</Year><Month>4</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2010</Year><Month>4</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2010</Year><Month>5</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">20423222</ArticleId><ArticleId IdType="doi">10.1086/652701</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Canada</li></country></list><tree><noCountry><name sortKey="Ferguson, Linda" sort="Ferguson, Linda" uniqKey="Ferguson L" first="Linda" last="Ferguson">Linda Ferguson</name><name sortKey="Frenette, Louise" sort="Frenette, Louise" uniqKey="Frenette L" first="Louise" last="Frenette">Louise Frenette</name><name sortKey="Fries, Louis" sort="Fries, Louis" uniqKey="Fries L" first="Louis" last="Fries">Louis Fries</name><name sortKey="Innis, Bruce" sort="Innis, Bruce" uniqKey="Innis B" first="Bruce" last="Innis">Bruce Innis</name><name sortKey="Johnson, Casey" sort="Johnson, Casey" uniqKey="Johnson C" first="Casey" last="Johnson">Casey Johnson</name><name sortKey="Kenney, Richard" sort="Kenney, Richard" uniqKey="Kenney R" first="Richard" last="Kenney">Richard Kenney</name><name sortKey="Li, Ping" sort="Li, Ping" uniqKey="Li P" first="Ping" last="Li">Ping Li</name><name sortKey="Riff, Dennis" sort="Riff, Dennis" uniqKey="Riff D" first="Dennis" last="Riff">Dennis Riff</name><name sortKey="Risi, George" sort="Risi, George" uniqKey="Risi G" first="George" last="Risi">George Risi</name><name sortKey="Sheldon, Eric" sort="Sheldon, Eric" uniqKey="Sheldon E" first="Eric" last="Sheldon">Eric Sheldon</name></noCountry><country name="Canada"><noRegion><name sortKey="Langley, Joanne M" sort="Langley, Joanne M" uniqKey="Langley J" first="Joanne M" last="Langley">Joanne M. Langley</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/GrippeCanadaV4/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000623 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000623 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= GrippeCanadaV4
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:20423222
|texte= Safety and cross-reactive immunogenicity of candidate AS03-adjuvanted prepandemic H5N1 influenza vaccines: a randomized controlled phase 1/2 trial in adults.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:20423222" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a GrippeCanadaV4
| This area was generated with Dilib version V0.6.35. |  |